Citizens JMP raised the firm’s price target on BeOne Medicines (ONC) to $396 from $348 and keeps an Outperform rating on the shares. BeOne Medicines reported a beat and raise quarter and provided corporate updates, including a preview of what will be an “exciting” 2025 ASH conference, the analyst tells investors in a research note. BeOne is positioning itself to dominate B cell malignancies through a portfolio that adapts as the treatment landscape evolves.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines Reports Strong Q3 2025 Growth
- BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating
- BeiGene’s Earnings Call: Record Growth and Positive Outlook
- BeOne Medicines reports Q3 non-GAAP EPS $2.65, consensus 86c
- BeOne Medicines narrows FY25 revenue view to $5.1B-$5.3B from $5.0B-$5.3B